Clinical Service, China   Report issue

For profit Phase 2
Founded: Beijing China (2004)
Status: Defunct (2015)

Organization Overview

First Clinical Trial
2010
NCT01328236
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2010

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (3)

bortezomib (velcade) (1 trial)

doxorubicin (Doxil) (1 trial)

urea (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Leukemia (Phase 2)

Leukemia, Plasma Cell (Phase 2)

Multiple Myeloma (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 3